Home Mental Health & Well-Being Clearmind Announces Agreement with Hebrew University Yissum Tech Transfer for Psychedelic Compounds to Treat Mental Disorders

Clearmind Announces Agreement with Hebrew University Yissum Tech Transfer for Psychedelic Compounds to Treat Mental Disorders

Published: Last updated:
Reading Time: < 1 minute

Clearmind Medicine Inc. (Nasdaq: CMND), (FSE: CWY0) (“Clearmind” or the “company”), a biotech company focused on discovery and development of novel psychedelic-derived therapeutics to solve major under-treated health problems, today announced an exclusive licensing agreement with Yissum Research Development Company of the Hebrew University of Jerusalem.

This partnership marks a significant step in harnessing generation 3.0 psychedelic compounds, the methods of their preparation, and the uses thereof in the treatment of addiction and mental disorders.

Dr Adi Zuloff-Shani, CEO of Clearmind, commented, “We are witnessing a renaissance within psychedelic medicine, including broad acknowledgment of these therapies and their potential by the medical community. While our existing IP portfolio includes molecules designed to address challenges inherent in classical psychedelics, we remain dedicated to continually enhancing our ongoing innovation.

“In particular, there has been a rise in demand for a new class of innovative compounds with enhanced psychedelic properties. We believe that these new generation 3.0 compounds hold enormous therapeutic potential as well as a strong safety profile.”

The exclusive licensing agreement with Yissum expands our IP portfolio of highly differentiated assets, strengthens our leadership position with potentially first-in-class assets, and illustrates our ongoing commitment to innovation. Our ultimate goal remains unchanged: to assist patients with unmet needs through the discovery of optimised psychedelic medications,” Dr Adi Zuloff-Shani added.

Under the terms of the agreement, Clearmind receives exclusive worldwide rights to develop, research, manufacture, market, and commercialise products derived from a patent-pending synthesis of psychedelic compounds, enriching the company’s innovative portfolio in addiction and mental health treatments.

© Copyright 2014–2034 Psychreg Ltd